Literature DB >> 11085546

Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy.

K Izuishi1, K Kato, T Ogura, T Kinoshita, H Esumi.   

Abstract

We hypothesized that the tolerance for nutrient deprivation as well as angiogenesis might be an important factor for tumor progression under hypovascular conditions. When normal human fibroblasts were subjected to extreme nutrient starvation by culturing in a medium without serum, glucose, and amino acids, cells died within 24 h. When substituted with liver cancer cell lines HepG2, Hep3B, HLE, and HuH-7, cell death occurred within 36 h. In contrast, four of six pancreas cancer cell lines, PANC-1, AsPC-1, BxPC-1, and KP-3, survived for remarkably longer periods; >50% of the cells survived, even after starvation for 48 h. Among three gastric cancer cell lines, MKN28, MKN45, and MKN74, only the most poorly differentiated MKN45 cells survived >36 h. More than 50% of the cells in colon cancer cell lines SW480, WiDr, and DLD-1 survived after 36 h, and the most undifferentiated SW480 cell line survived longest. We examined the possible involvement of PKB/Akt expression in the survival of various cell lines under nutrient starvation conditions. High expression of PKB/Akt was found to be associated with tolerance for nutrient starvation. When Akt antisense RNA expression vectors were introduced into PANC-1 cells, the tolerance was partially but significantly diminished by vectors for Akt1 and Akt2 but not Akt3. Because elimination of the tolerance might serve as a new strategy for cancer therapy, several compounds were tested for this purpose, and troglitazone, an insulin sensitizer, as well as LY294002, a phosphatidylinositol 3-kinase inhibitor, were found to kill PANC-1 cells only under nutrient starvation conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085546

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Curromycin A as a GRP78 downregulator and a new cyclic dipeptide from Streptomyces sp.

Authors:  Yoichi Hayakawa; Minami Akimoto; Akari Ishikawa; Masumi Izawa; Kazuo Shin-ya
Journal:  J Antibiot (Tokyo)       Date:  2015-11-25       Impact factor: 2.649

2.  Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.

Authors:  Chunyan Yang; Seung-Hee Jo; Balazs Csernus; Elizabeth Hyjek; Yifang Liu; Amy Chadburn; Y Lynn Wang
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.

Authors:  Claudia C S Chini; Jair M Espindola-Netto; Gourish Mondal; Anatilde M Gonzalez Guerrico; Veronica Nin; Carlos Escande; Mauro Sola-Penna; Jin-San Zhang; Daniel D Billadeau; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2015-12-11       Impact factor: 12.531

4.  Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges.

Authors:  Sandrina Maertin; Jason M Elperin; Ethan Lotshaw; Matthias Sendler; Steven D Speakman; Kazuki Takakura; Benjamin M Reicher; Olga A Mareninova; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-07-13       Impact factor: 4.052

5.  Bioactive Compounds from Medicinal Plants in Myanmar.

Authors:  Nwet Nwet Win; Hiroyuki Morita
Journal:  Prog Chem Org Nat Prod       Date:  2021

Review 6.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

Review 7.  Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.

Authors:  Haitham A Badr; Dina M M AlSadek; Motawa E El-Houseini; Christopher T Saeui; Mohit P Mathew; Kevin J Yarema; Hafiz Ahmed
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

8.  HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Authors:  Richard A Burkhart; Danielle M Pineda; Saswati N Chand; Carmella Romeo; Eric R Londin; Edward D Karoly; Joseph A Cozzitorto; Isidore Rigoutsos; Charles J Yeo; Jonathan R Brody; Jordan M Winter
Journal:  RNA Biol       Date:  2013-06-13       Impact factor: 4.652

9.  Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer.

Authors:  Shinichi Ota; Jean-Francois H Geschwind; Manon Buijs; Joost W Wijlemans; Byung Kook Kwak; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Target Oncol       Date:  2013-03-26       Impact factor: 4.493

10.  Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.

Authors:  Katherine B Philips; Metin Kurtoglu; Howard J Leung; Huaping Liu; Ningguo Gao; Mark A Lehrman; Timothy G Murray; Theodore J Lampidis
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-01       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.